Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

F. Köse



Author of

  • +

    P1.15 - Poster Session 1 - Thymoma (ID 189)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Thymoma & Other Thoracic Malignancies
    • Presentations: 1
    • +

      P1.15-005 - Multimodality treatment for thymoma and thymic carcinoma: Results of a single center experience. (ID 1665)

      09:30 - 09:30  |  Author(s): F. Köse

      • Abstract

      Background
      There are no randomized clinical trials that provide clear algorithm for the management of patients with thymoma or thymic carcinoma due to the rarity of these tumors.We review our experience with a multimodal approach in fourteen cases

      Methods
      Patients with thymoma and thymic carcinoma who were treated with multimodality treatment in our center between periods of 2006 and 2012 were retrospectively analyzed. Basic demographics, clinicalcharacteristics’ of the patients such as status of stage of tumor according to Masaoka Staging System, type of systemic chemotherapy, presence of paraneoplastic myasthenia gravis syndrome and surgical marginswere collected.

      Results
      Fourteen eligible patients were analyzed retrospectively. There were seven (50%) thymic carcinoma and seven (50%) thymoma. Included were 14 patients with a mean age of 50 years. Three patients (21.4%) had diagnosis of Myasthenia Gravis initially. There were four patients (28.6%), nine patients (64.3), one patient (7.1%) at stage II, Stage III, and stage IV, respectively. Nine patients were treated with multimodality treatment including surgery, chemoradiotherapy and adjuvant chemotherapy. Five patients were treated with chemoradiotherapy and adjuvant chemotherapy without surgical excision. Eight patients out of nine patients who were treated with primary surgery had positive resection margin (R1).Adjuvant protocol was consisted of cisplatin based chemotherapy. Median overall survival was 55 months (95% CI 11,4-98,5).One, two, and three year survival rate for thymoma was 85%, 85%, and 85%. Although, statistical analysis failed to show significant difference one, two, and three year survival rate for thymic carcinoma was inferior and found as 85%, 70%, and 43%, respectively. We were not able to show significant effects of patient and tumor baseline characteristics on overall survival.

      Conclusion
      Overall survival in our analysis seems to relatively inferior when compared with literature. We suggest that this result may be related with high rate of positive surgical margins and even absence of surgical excision in five patients a part of multimodal treatment.

  • +

    P1.22 - Poster Session 1 - Epidemiology, Etiology (ID 166)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Prevention & Epidemiology
    • Presentations: 1
    • +

      P1.22-004 - Pathologic subgroup analysis in patients who were diagnosed as non-small cell lung carcinoma and analysis of its effect together with basic demographic and clinical characteristics of patients on survival parameters. (ID 1673)

      09:30 - 09:30  |  Author(s): F. Köse

      • Abstract

      Background
      Lung cancer is the most common cause of cancer-related deaths in the world. In the last decades, the patients with adenocarcinoma histology have been increasing, although we don’t know the exact reason, and now constitute most common histological subgroup of Non-small Lung Carcinoma (NSCLC).Main aim of this study is analysis of histological subgroup of NSCLC, changing of histological subgroupsover time and its effect on survival parameters.

      Methods
      We analyzed 493 NSCLC patients those who were followed at our department between January 2006 and December 2011. Basic demographic and clinical characteristics such as stage of disease, initial diagnostic tests including invasive procedures, immunohistemochemical methods to clarify the histopathological subgroups, treatment protocols together with survival parameters were recorded retrospectively.

      Results
      Included were 493 patients with a median age of 60 years (35-102). There were 426 men (86.4%)and 67 women(13.6%)446 (90.5%) patients had a history of cigarette smoking. The percentage of female patients in whole group had been increased over timenonsignificantly(p=0.24). We found that adenocarcinoma was most common histopathological diagnosis (44.9%). Better performance status, early diagnosis, and adenocarcinoma histology exhibit statistically significant effect on overall survival with p values of (p=0.003,p=0.054, p=0.006), respectively. Statistical analysis showed that overall survival and TTF-1 positivity were significantly increased over time in the study with p values of (p=0.011) and (p=0,001) respectively. We also found that TTF-1 positivity was higher in female gender (p=0.005). Additionally,we were not able to show significant effects of basic demographic and clinical characteristicsof the patients such as age, TTF-1 positivity and primary localization of tumor on overall survival (p>0.05).

      Conclusion
      Our study showed that adenocarcinoma is the dominant histology of NSCLC in Turkey and the percentage of female patients in NSCLC and overall survival in NSCLC had been increased significantly over time.Patient and tumor characteristics, such as histological shifting to adenocarcinoma over time, that we found during our study is compatible with literature.